Navigation Links
Jury Returns Verdict in VNUS' Patent Infringement Lawsuit With Total Vein Systems and biolitec Finding Some Patent Claims Invalid and Some Infringed

HOUSTON, Dec. 9, 2010 /PRNewswire/ -- After a lengthy seven-week trial in VNUS' lawsuit against Total Vein Solutions, LLC d/b/a Total Vein Systems ("TVS") and biolitec, Inc. ("biolitec"), a federal jury in San Francisco has returned a verdict finding invalidity of many of the claims of VNUS' patents, and infringement of others.  

"TVS agrees with the jury's findings that certain claims in VNUS' '084, '803 and '355 patents were invalid as "obvious," but is displeased with the jury's verdict of infringement and damages."  Tyri Schiek, President and co-owner of TVS commented, "It has always been and remains our position that TVS does not infringe anyone's patents by selling unpatented, standard medical supplies.  We believe all of the VNUS method patents are invalid."   David Centanni, co-owner and CEO of TVS, added that "we disagree with the jury's conclusion on infringement and think the jury's findings on damages were grossly inflated.  TVS will continue business as usual and is confident that those findings of the jury that were in error will be overturned, either by the trial court or at the appellate level.  Total Vein remains dedicated to providing the highest quality medical products to physicians and clinics at fair and equitable prices."

VNUS sued TVS, among others, in 2008, for indirect patent infringement, by way of contributory and induced infringement, relating to TVS' sales of laser fibers, laser consoles, introducer kits and procedure packs.  The patents at issue do not cover a particular product or device, but instead claim a method of performing endovenous ablation with vein compression.  

TVS has steadfastly denied that its sales of unpatented products amount to infringing conduct.  TVS also noted that the patents do not adequately enable doctors to perform the methods using laser or microwave energy modalities without "undue experimentation," despite claiming such.  Moreover, TVS and biolitec argued that a variety of publications show that the same endovenous ablation methods existed long before, and that VNUS' claimed procedure is merely an obvious variant of such earlier described methods.  

TVS expects that it will file all necessary motions in the trial court to overturn the portions of the jury's decision that were in error, and will appeal where necessary.  Contact: David Centanni, CEO and co-ownerTyri Schiek, President and co-owner888 868-8346

SOURCE Total Vein Solutions, LLC d/b/a Total Vein Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Blood Donors Needed as School, Fall Season Returns
2. 2nd Annual Orthopedic Design & Technology Forum Returns April 28 to the FedEx Institute of Technology, University of Memphis
3. Allied Healthcare Products Returns to Profitability By Offsetting Depressed Sales with Cost Reductions
4. Molecular Devices Returns to Life Sciences Marketplace
5. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
6. Segal McCambridge Singer & Mahoney, Ltd. and Greenberg Traurig, LLP Obtain Three Defense Verdicts for I-Flow in Oregon Infusion Pump Cases
7. Jury Verdict Against Novartis Pharmaceuticals For Retaliating Against Drug Sales Rep Who Took Maternity Leave
8. Maryland Woman Thankful for Wyeth Verdicts
9. Published Study Shows VNUS ClosureFAST(TM) System Significantly Superior to Laser for Varicose Vein Treatment
10. NHS National Innovation Centre Cites VNUS Closure(R) Procedure as Select Innovative Technology
11. Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective
Post Your Comments:
(Date:10/11/2017)... -- Caris Life Sciences ® , a leading innovator in ... medicine, today announced that St. Jude Medical Center,s Crosson ... as its 17 th member. Through participation with ... Institute will help develop standards of care and best ... cancer treatment more precise and effective. ...
(Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
(Date:10/5/2017)... , Oct. 5, 2017  In response ... of Oral and Maxillofacial Surgeons (AAOMS) released prescribing ... – to be used as a first-line therapy ... Recognizing the ... AAOMS White Paper "Opioid Prescribing: Acute and Postoperative ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... BASKING RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... second annual Holly Day Market. Featuring a collection of specialty vendors and unique items ... myriad of personalized and quality-focused health and wellness services offered by the VNA. ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):